Table 2.

Therapeutic Regimens to be Considered for Potential Clearance of Moderate to Severe Plaque Psoriasis.

Regimen	Evidence for Disease Clearance or Near Clearance Within Approximately 3 Months of Therapy	Evidence for Disease Clearance or Near Clearance at Approximately 6 Months of Therapy	Evidence for Disease Clearance or Near Clearance Beyond 1 Year of Therapy	Notes
Adalimumab	Some patients may achieve 100% PASI reduction within 16 weeks of treatment. (LoE 1++50)	Some additional patients achieve/maintain 100% PASI reduction by 24 weeks of treatment. (LoE 2++50)	Some patients may achieve/maintain ≥90% PASI reduction through at least 160 weeks of treatment. (LoE 2+9)	Intended for ongoing continuous treatment
Ustekinumab	Some patients may achieve ≥90% PASI reduction by week 12 of treatment. (LoE 1+24-26)	Some patients may achieve/maintain ≥90% PASI reduction by week 28 of treatment. (LoE 1+24-26)	Some patients may maintain ≥90% PASI reduction through at least 244 weeks of treatment. (LoE 1+24)	Intended for ongoing continuous therapy.